Abelson J L, Curtis G C
Department of Psychiatry, University of Michigan, Ann Arbor, USA.
Am J Psychiatry. 1996 Jan;153(1):69-73. doi: 10.1176/ajp.153.1.69.
The authors sought to determine whether hypothalamic-pituitary-adrenal (HPA) axis activity in patients before their treatment for panic disorder can predict follow-up functional status. Although baseline HPA axis disturbances in patients with panic disorder appear to attenuate with treatment, there is evidence that they may be linked to poorer long-term outcomes.
Follow-up clinical data were obtained for 18 of 20 patients with panic disorder who participated in a detailed study of HPA axis activity in panic, both before and during their treatment with alprazolam. HPA axis assessment included monitoring of adrenocorticotropin and cortisol over a full circadian cycle. The relationships between disability and clinical status at 2-year follow-up and HPA axis overactivity at entry were examined.
Mean 24-hour cortisol levels before treatment provided a strong, positive predictor of disability scores at follow-up. Those patients who achieved the treatment goal of medication-free remissions had less evidence of HPA axis overactivity at entry than those who were not in remission.
HPA axis activity before treatment did predict outcome 2 years later. This relationship appears robust and reproducible. Further work is needed to define the neuroendocrine mechanisms underlying the HPA axis markers that are linked to long-term functioning and to determine the biological, psychological, and social processes that link HPA axis disturbance to poorer outcomes.
作者试图确定惊恐障碍患者在接受治疗前的下丘脑 - 垂体 - 肾上腺(HPA)轴活动是否能预测随访时的功能状态。尽管惊恐障碍患者的基线HPA轴紊乱在治疗后似乎会减轻,但有证据表明它们可能与较差的长期预后有关。
对20名参与惊恐障碍HPA轴活动详细研究的患者中的18名进行随访临床数据收集,这些患者在接受阿普唑仑治疗前及治疗期间均参与了研究。HPA轴评估包括在一个完整的昼夜周期内监测促肾上腺皮质激素和皮质醇。研究了入组时HPA轴活动亢进与2年随访时的残疾状况和临床状态之间的关系。
治疗前的平均24小时皮质醇水平是随访时残疾评分的一个强有力的正向预测指标。那些实现了无药物缓解治疗目标的患者,入组时HPA轴活动亢进的证据比未缓解的患者少。
治疗前的HPA轴活动确实能预测2年后的结果。这种关系似乎是稳健且可重复的。需要进一步开展工作来确定与长期功能相关的HPA轴标志物背后的神经内分泌机制,并确定将HPA轴紊乱与较差预后联系起来的生物学、心理和社会过程。